A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Johannes Gutenberg University Mainz, Yonsei University, Gangnam Severance Hospital, Korea University Anam Hospital, Seoul National University Bundang Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, The University of Texas MD Anderson Cancer Center, Saitama Cancer Center, Bristol-Myers Squibb (United States), Seoul National University Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2758580246